2-ethyl-4-methylfuran | 55357-91-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-ethyl-4-methylfuran
• CAS: 55357-91-0
• 化学式: C₇H₁₀O
• 分子量: 110.156
• InChiKey: ZRTCPDWNLQSTLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-ethyl-2-methyl-4-methylene-[1,3]dioxolane 生成 2-ethyl-4-methylfuran
  参考文献：
  名称：

  SCHARF H.-D.; WOLTERS E., CHEM. BER. , 1978, 111, NO 2, 639-660

  摘要：

  DOI：

文献信息

• 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
  申请人：GiraFpharma LLC

  公开号：US20190023702A1

  公开（公告）日：2019-01-24

  1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了作为腺苷受体调节剂的1,8-萘啶酮化合物。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• [EN] ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE<br/>[FR] ANALOGUES D'ADÉNOSINE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOINTERVENE INC

  公开号：WO2020247546A1

  公开（公告）日：2020-12-10

  The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.

  该披露提供了用于治疗疾病，如疼痛和炎症症状的腺苷类似物。
• NOVEL HALOGEN-SUBSTITUTED COMPOUNDS
  申请人：BAYER CROPSCIENCE AKTIENGESELLSCHAFT

  公开号：US20170137413A1

  公开（公告）日：2017-05-18

  The invention relates inter alia to halogen-substituted compounds of the general formula (I) in which the A 1 -A 4 , T, W, Q, R 1 and Z 1 -Z 3 radicals are as defined in the description. Also described are processes for preparing the compounds of the formula (I). The compounds according to the invention are especially suitable for controlling insects, arachnids and nematodes in agriculture, and ectoparasites in veterinary medicine.

  该发明涉及一般式（I）的卤素取代化合物，其中A1-A4，T，W，Q，R1和Z1-Z3基团如描述中所定义。还描述了制备式（I）化合物的过程。该发明的化合物特别适用于农业中控制昆虫、蜘蛛和线虫，以及兽医学中的外寄生虫。
• Pyridine Derivatives
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20130085148A1

  公开（公告）日：2013-04-04

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。同时还提供了制备这些化合物的方法。这些化合物可以通过向患者投予治疗有效量的一个或多个化合物来抑制CYP17活性。通过这样做，这些化合物对于治疗与CPY17活性相关的疾病是有效的。这些化合物可以用于治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症，如前列腺癌。
• PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PDE10 INHIBITOR
  申请人：Omeros Corporation

  公开号：US20160024069A1

  公开（公告）日：2016-01-28

  The present invention is directed to an improved process for the preparation of compounds of Formula (II) and Formula (III), which are useful in the inhibition of PDE10. In particular, the present invention is directed to an improved process for the preparation of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, which is useful in the inhibition of PDE10.

  本发明涉及一种改进的制备公式（II）和公式（III）化合物的方法，该化合物在抑制PDE10方面有用。具体而言，本发明涉及一种改进的制备1-（5-（4-氯-3,5-二甲氧基苯基）呋喃-2-基）-2-乙氧基-2-（4-（5-甲基-1,3,4-噻二唑-2-基）苯基）乙酮的方法，该化合物在抑制PDE10方面有用。